Definium Therapeutics (NASDAQ:DFTX) Hits New 12-Month High – Should You Buy?

Definium Therapeutics, Inc. (NASDAQ:DFTX)’s share price reached a new 52-week high during mid-day trading on Monday . The stock traded as high as $40.02 and last traded at $40.02, with a volume of 2749393 shares changing hands. The stock had previously closed at $24.48.

Analyst Ratings Changes

DFTX has been the subject of several recent research reports. Leerink Partners boosted their price objective on Definium Therapeutics from $23.00 to $30.00 and gave the stock an “outperform” rating in a report on Wednesday, April 22nd. Oppenheimer reissued an “outperform” rating and set a $40.00 price target on shares of Definium Therapeutics in a research note on Thursday, April 23rd. Canaccord Genuity Group restated a “buy” rating and issued a $38.00 price objective on shares of Definium Therapeutics in a report on Tuesday, June 16th. HC Wainwright lifted their target price on shares of Definium Therapeutics from $55.00 to $70.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. Finally, Stifel Nicolaus set a $30.00 price target on Definium Therapeutics and gave the company a “buy” rating in a research note on Thursday, April 16th. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $37.92.

Definium Therapeutics Price Performance

The company has a 50-day moving average of $22.68 and a 200-day moving average of $18.40. The company has a debt-to-equity ratio of 0.15, a quick ratio of 4.69 and a current ratio of 4.69. The firm has a market capitalization of $3.58 billion, a price-to-earnings ratio of -14.41 and a beta of 2.37.

Definium Therapeutics (NASDAQ:DFTX) last released its quarterly earnings results on Friday, May 8th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.23). As a group, research analysts anticipate that Definium Therapeutics, Inc. will post -2.3 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Palumbo Wealth Management LLC boosted its holdings in shares of Definium Therapeutics by 18.4% during the fourth quarter. Palumbo Wealth Management LLC now owns 39,002 shares of the company’s stock worth $522,000 after acquiring an additional 6,073 shares during the period. Flagship Harbor Advisors LLC acquired a new stake in Definium Therapeutics during the 4th quarter worth approximately $117,000. Bay Rivers Group boosted its stake in Definium Therapeutics by 14.3% in the 4th quarter. Bay Rivers Group now owns 16,001 shares of the company’s stock valued at $214,000 after purchasing an additional 2,000 shares during the period. FNY Investment Advisers LLC acquired a new position in Definium Therapeutics in the 3rd quarter valued at $107,000. Finally, Caxton Associates LLP bought a new position in Definium Therapeutics during the 3rd quarter worth $126,000. Institutional investors and hedge funds own 27.91% of the company’s stock.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.